[Therapy of cardiac arrhythmias. Clinical significance of potassium- and magnesium aspartate in arrhythmias].
Potassium and magnesium deficiencies usually coexist and represent a risk factor for cardiac arrhythmias. Serum levels--in particular of magnesium--are inconclusive for establishing a possible electrolyte deficiency. Basic treatment of arrhythmia should therefore include the administration of potassium and magnesium, since the benefit is great, and the possible side effects is negligible. A placebo-controlled study involving patients with cardiac arrhythmias revealed that appreciably fewer ventricular asystoles occurred after three weeks of treatment with potassium and magnesium aspartate, even when serum levels were within the normal range prior to initiating treatment. Patients older than 50, and those with previous coronary heart disease and/or myocardial infarction derived particular benefit from this form of treatment.


CONCLUSIONS
These results underscore the key role played by potassium and magnesium in the treatment of cardiac arrhythmias.
D000328:Adult; D000368:Aged; D001224:Aspartic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008274:Magnesium / Q000097:blood; D008275:Magnesium Deficiency / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011191:Potassium Deficiency / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D012189:Retrospective Studies; D018879:Ventricular Premature Complexes / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*
D004338:Drug Combinations; D001224:Aspartic Acid; D008274:Magnesium; D011188:Potassium